Journal: JAAD Case Reports

Article Title: Treatment of extramammary Paget’s disease with sirolimus: A case series

doi: 10.1016/j.jdcr.2025.10.021

Figure Lengend Snippet: Clinical images of patient 1 at baseline (A) , 8 wks on sirolimus twice daily (B) , and 16 wks on sirolimus twice daily (C) .

Article Snippet: While the pathogenesis of EMPD is not completely understood, the Musashi-1- mammalian target of rapamycin signaling pathway is thought to play a role in disease development.

Techniques:

Journal: JAAD Case Reports

Article Title: Treatment of extramammary Paget’s disease with sirolimus: A case series

doi: 10.1016/j.jdcr.2025.10.021

Figure Lengend Snippet: Clinical images of patient 3 at baseline (A) , 4 wks on sirolimus twice daily (B) , and 8 wks on sirolimus twice daily (C) .

Article Snippet: While the pathogenesis of EMPD is not completely understood, the Musashi-1- mammalian target of rapamycin signaling pathway is thought to play a role in disease development.

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: Diallyl Disulfide Mitigates LPS-Induced Inhibition of Osteogenic Differentiation and Alleviates Inflammatory Bone Loss via PI3K/AKT Signaling Pathway

doi: 10.2147/DDDT.S590959

Figure Lengend Snippet: DADS activates the PI3K/AKT signaling pathway. ( A – D ) Representative images reflecting the expression levels of p-PI3K, PI3K, p-AKT, and AKT, along with their quantification, with total protein serving as a loading control. Statistical analysis was performed using one-way ANOVA. Data are presented as mean ± SD, n = 5 independent biological replicates per group. Exact P values for pairwise comparisons are shown above the horizontal lines; P < 0.001 denotes values below three-decimal precision.

Article Snippet: Furthermore, when validating the mechanism related to the PI3K/AKT signaling pathway, 10 μM PI3K inhibitor LY294002 (MedChemExpress, Shanghai, China) was added to the LPS+DADS high-dose group.

Techniques: Expressing, Control

Journal: Drug Design, Development and Therapy

Article Title: Diallyl Disulfide Mitigates LPS-Induced Inhibition of Osteogenic Differentiation and Alleviates Inflammatory Bone Loss via PI3K/AKT Signaling Pathway

doi: 10.2147/DDDT.S590959

Figure Lengend Snippet: DADS rescues LPS-induced inhibition of osteogenic differentiation by activating the PI3K/AKT signaling pathway. ( A ) Representative images of ALP staining (scale bar = 100 μm). ( B ) ALP activity evaluation after 7 days of osteogenic induction. ( C ) Representative images of Alizarin Red staining after 14 days of osteogenic induction (scale bar = 100 μm). ( D ) Quantitative assessment of the calcium deposition in ( C ). ( E – H ) The expression of osteogenic-specific genes COL1A1, RUNX2, ALP, and OCN after 7 days of osteogenic induction. ( I – K ) Western blot and quantitative analysis of the levels of osteogenic markers COL1A1 and RUNX2 after 7 days of osteogenic induction, with total protein serving as a loading control. Statistical analysis was performed using one-way ANOVA. Data are presented as mean ± SD, n = 5 independent biological replicates per group. Exact P values for pairwise comparisons are shown above the horizontal lines; P < 0.001 denotes values below three-decimal precision.

Article Snippet: Furthermore, when validating the mechanism related to the PI3K/AKT signaling pathway, 10 μM PI3K inhibitor LY294002 (MedChemExpress, Shanghai, China) was added to the LPS+DADS high-dose group.

Techniques: Inhibition, Staining, Activity Assay, Expressing, Western Blot, Control